Tianjin CanSino Biotechnology

Tianjin CanSino Biotechnology Inc. (CanSinoBIO) is a biopharmaceutical firm established in 2009, specializing in the research, development, manufacturing, and commercialization of vaccines. The company was founded in Tianjin, China, by a group of scientists—Yu Xuefeng, Zhu Tao, Qiu Dongxu, and Helen Mao Huihua—who returned after extensive careers at global pharmaceutical companies in the United States and Canada. This international experience is a cornerstone of the company's operational and scientific strategy; for instance, CEO Yu Xuefeng previously served as the director of bacterial vaccine development at Sanofi Pasteur in Canada. CanSinoBIO's strategic financing milestones include a successful initial public offering on the Hong Kong Stock Exchange in March 2019, followed by a secondary listing on the Shanghai Stock Exchange's STAR Market in August 2020.

The company's business model centers on developing and selling vaccines to address infectious diseases globally, serving clients such as governments and public health organizations. Revenue is generated primarily through the sale of its commercialized vaccine products. CanSinoBIO employs a hybrid "direct sales + CSO" distribution model to penetrate markets. Operationally, the company has established large-scale manufacturing facilities in Tianjin and Shanghai and has expanded its global footprint with fill-and-finish production lines in Mexico, Pakistan, and Malaysia.

CanSinoBIO's product portfolio is built upon five integrated technology platforms, including adenovirus-based viral vectors, mRNA, and protein structure design. A significant achievement was the development of its single-dose adenovirus-vectored COVID-19 vaccine, Convidecia (Ad5-nCoV), which gained World Health Organization (WHO) emergency use listing and has been approved in numerous countries. The company further developed the world's first inhaled version of a COVID-19 vaccine, Convidecia Air®, approved as a booster dose in China, Morocco, and Indonesia. Beyond COVID-19, its commercialized products include Menhycia® (a quadrivalent meningococcal conjugate vaccine), Menphecia® (a bivalent meningococcal conjugate vaccine), and Ad5-EBOV for the Ebola virus. The product pipeline is robust, featuring candidates for pneumonia (iPneucia®, a 13-valent pneumococcal conjugate vaccine launched in June 2025), tuberculosis, diphtheria, tetanus, and polio, among others.

Keywords: vaccine development, biopharmaceutical, CanSino Biologics, infectious disease prevention, Convidecia, Ad5-nCoV, inhaled vaccine, meningococcal vaccine, pneumococcal vaccine, Ebola vaccine, Yu Xuefeng, adenovirus vector technology, public health, vaccine manufacturing, Menhycia, Menphecia, COVID-19 booster, clinical trials, biopharma China, global health security, combination vaccines, mRNA technology, vaccine pipeline, immunology, epidemiology, drug delivery systems, biologics commercialization